Tang Qi, Liu Yue-Fang, Zhu Xiao-Jing, Li Yu-Hua, Zhu Jin, Zhang Jian-Ping, Feng Zhen-Qing, Guan Xiao-Hong
Key Laboratory of Antibody Technique, Ministry of Health, Nanjing Medical University, Nanjing 210029, PR China.
Hum Pathol. 2009 Mar;40(3):300-5. doi: 10.1016/j.humpath.2008.09.002. Epub 2008 Nov 7.
The aim of this study was to characterize expression of the alpha B-crystallin gene in human hepatocellular carcinomas, to investigate the relationship between expression of this gene and the prognosis of human hepatocellular carcinoma. Real-time polymerase chain reaction, reverse transcriptase-polymerase chain reaction and immunohistochemistry were used to characterize expression of the alpha B-crystallin gene in human hepatocellular carcinoma. Kaplan-Meier survival and Cox regression analyses were performed to evaluate the prognosis of human hepatocellular carcinoma. We characterized alpha B-crystallin gene expression in human hepatocellular carcinoma. Statistical analysis of hepatocellular carcinoma patients showed that patients expressing alpha B-crystallin have different survival rates relative to those not expressing this gene (P = .041). After 18 months, the survival rate of patients expressing alpha B-crystallin declined, but survival in the alpha B-crystallin-negative group remained stable. COX multi-factor analysis showed that alpha B-crystallin (P = .007) and venous invasion (P = .037) were independent prognosis factors for hepatocellular carcinoma. Expression of the alpha B-crystallin gene, which is related with the transferability and invasive capacity of hepatocellular carcinoma cells, can be used as a prognostic indicator in human hepatocellular carcinomas. It may also be involved in the malignant transformation of hepatocytes.
本研究旨在表征αB-晶状体蛋白基因在人肝细胞癌中的表达情况,探讨该基因表达与人肝细胞癌预后之间的关系。采用实时聚合酶链反应、逆转录聚合酶链反应和免疫组织化学方法表征αB-晶状体蛋白基因在人肝细胞癌中的表达。进行Kaplan-Meier生存分析和Cox回归分析以评估人肝细胞癌的预后。我们表征了αB-晶状体蛋白基因在人肝细胞癌中的表达。对肝细胞癌患者的统计分析表明,表达αB-晶状体蛋白的患者与未表达该基因的患者相比,生存率不同(P = 0.041)。18个月后,表达αB-晶状体蛋白的患者生存率下降,但αB-晶状体蛋白阴性组的生存率保持稳定。COX多因素分析表明,αB-晶状体蛋白(P = 0.007)和静脉侵犯(P = 0.037)是肝细胞癌的独立预后因素。αB-晶状体蛋白基因的表达与肝癌细胞的转移能力和侵袭能力相关,可作为人肝细胞癌的预后指标。它也可能参与肝细胞的恶性转化。